Search

Your search keyword '"Chic, N."' showing total 157 results
Start Over Author "Chic, N."
157 results on '"Chic, N."'

2. Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer

Author

Griguolo, G., Serna, G., Pascual, T., Fasani, R., Guardia, X., Chic, N., Paré, L., Pernas, S., Muñoz, M., Oliveira, M., Vidal, M., Llombart-Cussac, A., Cortés, J., Galván, P., Bermejo, B., Martínez, N., López, R., Morales, S., Garau, I., Manso, L., Alarcón, J., Martínez, E., Villagrasa, P., Prat, A., and Nuciforo, P.

Published
2021
Full Text
View/download PDF

3. Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism

Author

Moustafa, Farès, Giorgi Pierfranceschi, Matteo, Di Micco, Pierpaolo, Bucherini, Eugenio, Lorenzo, Alicia, Villalobos, Aurora, Nieto, José A., Valero, Beatriz, Sampériz, Ángel L., Monreal, Manuel, Decousus, Hervé, Prandoni, Paolo, Brenner, Benjamin, Barba, Raquel, Bertoletti, Laurent, Tzoran, Inna, Reis, Abilio, Bosevski, Marijan, Bounameaux, Henri, Malý, Radovan, Wells, Philip, Papadakis, Manolis, Adarraga, MD, Agudo, P, Aibar, MA, Alfonso, M, Arcelus, JI, Ballaz, A, Barba, R, Barrón, M, Barrón‐Andrés, B, Bascuñana, J, Blanco‐Molina, A, Cañas, I, Casado, I, Chic, N, del Pozo, R, del Toro, J, Díaz‐Pedroche, MC, Díaz‐Peromingo, JA, Falgá, C, Fernández‐Aracil, C, Fernández‐Capitán, C, Fidalgo, MA, Font, C, Font, L, Gallego, P, García, MA, García‐Bragado, F, Gavín, O, Gómez, C, Gómez, V, González, J, Grau, E, Grimón, A, Guijarro, R, Guirado, L, Gutiérrez, J, Hernández‐Comes, G, Hernández‐Blasco, L, Jara‐Palomares, L, Jaras, MJ, Jiménez, D, Jiménez, J, Joya, MD, Llamas, P, Lobo, JL, López, P, López‐Jiménez, L, López‐Reyes, R, López‐Sáez, JB, Lorente, MA, Lumbierres, M, Luque, JM, Marchena, PJ, Martín‐Martos, F, Mellado, M, Nieto, S, Núñez, A, Núñez, MJ, Otalora, S, Otero, R, Pedrajas, JM, Pérez, G, Pérez‐Ductor, C, Peris, ML, Pons, I, Porras, JA, Reig, O, Riera‐Mestre, A, Riesco, D, Rivas, A, Rodríguez, M, Rodríguez‐Dávila, MA, Rosa, V, Rosillo‐Hernández, E, Ruiz‐Artacho, P, Ruiz‐Giménez, N, Sahuquillo, JC, Sala‐Sainz, MC, Sánchez‐Martínez, R, Sanz, O, Soler, S, Sopeña, B, Suriñach, JM, Tolosa, C, Torres, MI, Troya, J, Trujillo‐Santos, J, Uresandi, F, Usandizaga, E, Valle, R, Vela, J, Vela, L, Vicente, MP, Xifre, B, Vanassche, T, Verhamme, P, Yoo, HHB, Wells, P, Hirmerova, J, Malý, R, Dulíček, P, Salgado, E, Bertoletti, L, Bura‐Riviere, A, Farge‐Bancel, D, Hij, A, Mahé, I, Merah, A, Braester, A, Brenner, B, Tzoran, I, Antonucci, G, Barillari, G, Bilora, F, Bortoluzzi, C, Brandolin, B, Cattabiani, C, Ciammaichella, M, Dell'Elce, N, Dentali, F, Duce, R, Grandone, E, Imbalzano, E, Lessiani, G, Maida, R, Mastroiacovo, D, Pace, F, Parisi, R, Pellegrinet, M, Pesavento, R, Pinelli, M, Poggio, R, Prandoni, P, Quintavalla, R, Rocci, A, Tiraferri, E, Tonello, D, Tufano, A, Visonà, A, Gibietis, V, Skride, A, Vitola, B, Bosevski, M, Zdraveska, M, Bounameaux, H, and Mazzolai, L

Published
2017
Full Text
View/download PDF

4. Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism

Author

Monreal, Manuel, Decousus, Hervè, Prandoni, Paolo, Brenner, Benjamin, Barba, Raquel, Di Micco, Pierpaolo, Bertoletti, Laurent, Tzoran, Inna, Reis, Abilio, Bosevski, Marijan, Bounameaux, Henri, Malý, Radovan, Wells, Philip, Verhamme, Peter, Adarraga, M.D., Aibar, M.A., Alfonso, M., Arcelus, J.I., Azcarate-Agüero, P.M., Ballaz, A., Barba, R., Barrón, M., Barrón-Andrés, B., Bascuñana, J., Blanco-Molina, A., Cañada, G., Cañas, I., Casado, I., Chic, N., del Pozo, R., del Toro, J., Díaz-Pedroche, M.C., Díaz-Peromingo, J.A., Falgá, C., Fernández-Aracil, C., Fernández-Capitán, C., Fidalgo, M.A., Font, C., Font, L., Gallego, P., García, M.A., García-Bragado, F., García-Brotons, P., Gavín, O., Gómez, C., Gómez, V., González, J., Grau, E., Grimón, A., Guirado, L., Gutiérrez, J., Hernández-Comes, G., Hernández-Blasco, L., Jara-Palomares, L., Jaras, M.J., Jiménez, D., Jiménez, J., Joya, M.D., Llamas, P., Lobo, J.L., López, P., López-Jiménez, L., López-Reyes, R., López-Sáez, J.B., Lorente, M.A., Lorenzo, A., Luque, J.M., Marchena, P.J., Martínez, C., Martín-Martos, F., Monreal, M., Nieto, J.A., Nieto, S., Núñez, A., Núñez, M.J., Otalora, S., Otero, R., Pedrajas, J.M., Pérez, G., Pérez-Ductor, C., Peris, M.L., Pons, I., Porras, J.A., Reig, O., Riera-Mestre, A., Riesco, D., Rivas, A., Rodríguez, M., Rodríguez-Dávila, M.A., Rosa, V., Sahuquillo, J.C., Sala-Sainz, M.C., Sampériz, A., Sánchez-Martínez, R., Sanz, O., Soler, S., Sopeña, B., Suriñach, J.M., Tolosa, C., Torres, M.I., Trujillo-Santos, J., Uresandi, F., Usandizaga, E., Valero, B., Valle, R., Vela, J., Vidal, G., Vilar, C., Xifre, B., Vanassche, T., Verhamme, P., Yoo, H.H.B., Wells, P., Hirmerova, J., Malý, R., Salgado, E., Bertoletti, L., Bura-Riviere, A., Farge-Bancel, D., Hij, A., Mahé, I., Merah, A., Moustafa, F., Braester, A., Brenner, B., Tzoran, I., Antonucci, G., Barillari, G., Bilora, F., Bonanome, A., Bortoluzzi, C., Brandolin, B., Ciammaichella, M., De Ciantis, P., Dentali, F., Di Micco, P., Duce, R., Giorgi-Pierfranceschi, M., Grandone, E., Imbalzano, E., Lessiani, G., Maida, R., Mastroiacovo, D., Pace, F., Parisi, R., Pesavento, R., Pinelli, M., Poggio, R., Prandoni, P., Quintavalla, R., Rocci, A., Tiraferri, E., Tonello, D., Tufano, A., Venturelli, U., Visonà, A., Gibietis, V., Skride, A., Vitola, B., Bosevski, M., Zdraveska, M., Bounameaux, H., Mazzolai, L., Barrios, Deisy, Chavant, Jeremy, Jiménez, David, Rosa-Salazar, Vladimir, Muriel, Alfonso, Viallon, Alain, Fernández-Capitán, Carmen, and Yusen, Roger D.

Published
2017
Full Text
View/download PDF

5. Development of a Risk Prediction Score for Occult Cancer in Patients With VTE

Author

Monreal, Manuel, Decousus, Hervè, Prandoni, Paolo, Brenner, Benjamin, Barba, Raquel, Di Micco, Pierpaolo, Bertoletti, Laurent, Tzoran, Inna, Reis, Abilio, Bosevski, Marijan, Bounameaux, Henri, Malý, Radovan, Wells, Philip, Papadakis, Manolis, Aibar, M.A., Alfonso, M., Asensio-Cruz, M.I., Auguet, T., Arcelus, J.I., Barba, R., Barrón, M., Barrón-Andrés, B., Bascuñana, J., Blanco-Molina, A., Bueso, T., Cañas, I., Ceausu, A., Chic, N., Culla, A., del Pozo, R., del Toro, J., Díaz-Pedroche, M.C., Díaz-Peromingo, J.A., Duffort, M., Elias-Hernández, T., Falgá, C., Fernández-Aracil, C., Fernández-Capitán, C., Fidalgo, M.A., Font, C., Font, L., Gallego, P., García, M.A., García-Bragado, F., García-Rodenas, M., Gómez, V., González, J., Grau, E., Grimón, A., Guijarro, R., Guirado, L., Gutiérrez, J., Hernández-Comes, G., Hernández-Blasco, L., Hernando-López, E., Jara-Palomares, L., Jaras, M.J., Jiménez, D., Joya, M.D., Llamas, P., Lecumberri, R., Lobo, J.L., López-Jiménez, L., López-Reyes, R., López-Sáez, J.B., Lorente, M.A., Lorenzo, A., Maestre, A., Marchena, P.J., Martín, M., Martín-Martos, F., Monreal, M., Nieto, J.A., Nieto, S., Núñez, A., Núñez, M.J., Odriozola, M., Otalora, S., Otero, R., Ovejero, A., Pedrajas, J.M., Pérez, G., Pérez-Ductor, C., Peris, M.L., Porras, J.A., Reig, O., Riera-Mestre, A., Riesco, D., Rivas, A., Rodríguez-Dávila, M.A., Rosa, V., Ruiz-Artacho, P., Ruiz-Giménez, N., Sahuquillo, J.C., Sala-Sainz, M.C., Sampériz, A., Sánchez, R., Sanz, O., Soler, S., Sopeña, B., Suriñach, J.M., Tolosa, C., Trujillo-Santos, J., Uresandi, F., Valero, B., Valle, R., Vela, J., Vicente, P., Vidal, G., Villalobos, A., Villalta, J., Vanassche, T., Verhamme, P., Wells, P., Hirmerova, J., Malý, R., Salgado, E., Bertoletti, L., Bura-Riviere, A., Farge-Bancel, D., Hij, A., Mahé, I., Merah, A., Moustafa, F., Papadakis, M., Braester, A., Brenner, B., Tzoran, I., Antonucci, G., Barillari, G., Bertone, A., Bilora, F., Bortoluzzi, C., Ciammaichella, M., Di Girolamo, C., Di Micco, P., Duce, R., Ferrazzi, P., Giorgi-Pierfranceschi, M., Grandone, E., Lodigiani, C., Maida, R., Mastroiacovo, D., Pace, F., Pesavento, R., Pinelli, M., Poggio, R., Prandoni, P., Rota, L., Tiraferri, E., Tonello, D., Tufano, A., Visonà, A., Zalunardo, B., Drucka, E., Kigitovica, D., Skride, A., Sousa, M.S., Bosevski, M., Zdraveska, M., Bounameaux, H., Mazzolai, L., Jara-Palomares, Luis, Otero, Remedios, Jimenez, David, Carrier, Marc, Margeli, Mireia, Praena-Fernandez, Juan Manuel, and Grandone, Elvira

Published
2017
Full Text
View/download PDF

6. Analysis of noncatheter-associated upper extremity deep venous thrombosis from the RIETE registry

Author

Monreal, Manuel, Decousus, Hervè, Prandoni, Paolo, Brenner, Benjamin, Barba, Raquel, Di Micco, Pierpaolo, Bertoletti, Laurent, Tzoran, Inna, Reis, Abilio, Bosevski, Marijan, Bounameaux, Henri, Malý, Radovan, Wells, Philip, Papadakis, Manolis, Agüero, R., Aibar, M.A., Alfonso, M., Aranda, R., Arcelus, J.I., Barba, R., Barrón, M., Barrón-Andrés, B., Bascuñana, J., Binetti, J., Blanco-Molina, A., Bueso, T., Cañas, I., Carmona, F., Chic, N., Culla, A., del Pozo, R., del Toro, J., Díaz-Pedroche, M.C., Díaz-Peromingo, J.A., Falgá, C., Fernández-Aracil, C., Fernández-Capitán, C., Fidalgo, M.A., Font, C., Font, L., Gallego, P., García, M.A., García-Bragado, F., Gómez, V., González, J., Grau, E., Grimón, A., Guirado, L., Gutiérrez, J., Hernández-Comes, G., Hernández-Blasco, L., Jara-Palomares, L., Jaras, M.J., Jiménez, D., Joya, M.D., Lecumberri, R., Lobo, J.L., López-Jiménez, L., López-Reyes, R., López-Sáez, J.B., Lorente, M.A., Lorenzo, A., Manrique-Abos, I., Marchena, P.J., Martín, M., Martín-Antorán, J.M., Martín-Martos, F., Monreal, M., Nieto, J.A., Nieto, S., Núñez, A., Núñez, M.J., Otalora, S., Otero, R., Pagán, B., Pedrajas, J.M., Pérez, G., Pérez, I., Pérez-Ductor, C., Peris, M.L., Porras, J.A., Reig, O., Riera-Mestre, A., Riesco, D., Rivas, A., Rodríguez-Dávila, M.A., Rosa, V., Rosillo-Hernández, E., Ruiz-Artacho, P., Ruiz-Giménez, N., Sahuquillo, J.C., Sala-Sainz, M.C., Sampériz, A., Sánchez, R., Sanz, O., Soler, S., Sopeña, B., Suriñach, J.M., Tolosa, C., Trujillo-Santos, J., Uresandi, F., Valero, B., Valle, R., Vela, J., Vidal, G., Villalta, J., Vanassche, T., Verhamme, P., Wells, P., Hirmerova, J., Malý, R., Salgado, E., Bertoletti, L., Bura-Riviere, A., Champion, K., Farge-Bancel, D., Hij, A., Mahé, I., Merah, A., Papadakis, M., Braester, A., Brenner, B., Tzoran, I., Antonucci, G., Barillari, G., Bilora, F., Ciammaichella, M., Dentali, F., Di Micco, P., Duce, R., Ferrazzi, P., Grandone, E., Lodigiani, C., Maida, R., Pace, F., Pesavento, R., Poggio, R., Prandoni, P., Rota, L., Tiraferri, E., Tonello, D., Tufano, A., Visonà, A., Zalunardo, B., Drucka, E., Kigitovica, D., Skride, A., Ramos, A.R., Ribeiro, J.L., Sousa, M.S., Bosevski, M., Zdraveska, M., Bounameaux, H., Erdmann, A., Mazzolai, L., Ney, B., Newton, Daniel H., Monreal Bosch, Manuel, Amendola, Michael, Wolfe, Luke, Perez Ductor, Cristina, Lecumberri, Ramón, and Levy, Mark M.

Published
2017
Full Text
View/download PDF

7. 8P First decision impact study of HER2DX in patients (pts) with HER2-positive (HER2+) early breast cancer

Author

Saez, O. Martinez, primary, Brasó-Maristany, F., additional, Marín-Aguilera, M., additional, Losada, M.J. Vidal, additional, Adamo, B., additional, Pascual, T., additional, Schettini, F., additional, Conte, B., additional, Chic, N., additional, Bravo, R. Gomez, additional, Fructuoso, I. Garcia, additional, Solis, E. Segui, additional, Galván, P., additional, Hernández-Illán, E., additional, Jares, P., additional, Puig-Butille, J.A., additional, Torres, E. Sanfeliu, additional, Brunet, L. Pare, additional, Gonzalez, P. Villagrasa, additional, and Munoz, M., additional

Published
2023
Full Text
View/download PDF

8. 237P HER2DX genomic assay in advanced HER2-positive (HER2+) breast cancer treated with T-DM1

Author

Brasó-Maristany, F., primary, Griguolo, G., additional, Chic, N., additional, Pare Brunet, L., additional, Galván, P., additional, Dieci, M.V., additional, Miglietta, F., additional, Giarratano, T., additional, Martínez-Sáez, O., additional, Marin, M., additional, Vidal Losada, M.J., additional, Adamo, B., additional, Munoz, M., additional, Vivancos, A., additional, Villagrasa Gonzalez, P., additional, Parker, J., additional, Perou, C.M., additional, Conte, P.F., additional, Prat, A., additional, and Guarneri, V., additional

Published
2022
Full Text
View/download PDF

9. 153P HER2DX risk-score in the context of the PREDICT online-tool: A correlative analysis of the Short-HER clinical trial in early-stage HER2-positive (HER2+) breast cancer (BC)

Author

Conte, P.F., primary, Pare Brunet, L., additional, Brasó-Maristany, F., additional, Chic, N., additional, Martinez Saez, O., additional, Dieci, M.V., additional, Marin, M., additional, Guarneri, V., additional, Vivancos, A., additional, Villagrasa Gonzalez, P., additional, Parker, J., additional, Perou, C.M., additional, and Prat, A., additional

Published
2022
Full Text
View/download PDF

10. 263P Clinical outcomes in patients with germline pathogenic variants in homologous recombination repair (HRR) genes treated with CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET)

Author

Rodriguez Hernandez, A., primary, Martinez Saez, O., additional, Brasó-Maristany, F., additional, Pastor, B., additional, Potrony, M., additional, Moreno, L., additional, Grau, E., additional, Puig-Butille, J.A., additional, Sánchez, A., additional, Schettini, F., additional, Conte, B., additional, Chic, N., additional, Vidal Losada, M.J., additional, Munoz, M., additional, Balaguer, F., additional, Prat, A., additional, and Adamo, B., additional

Published
2022
Full Text
View/download PDF

11. Development of a Risk Prediction Score for Occult Cancer in Patients With VTE

Author

Jara-Palomares, Luis, Otero, Remedios, Jimenez, David, Carrier, Marc, Tzoran, Inna, Brenner, Benjamin, Margeli, Mireia, Praena-Fernandez, Juan Manuel, Grandone, Elvira, Monreal, Manuel, Monreal, Manuel, Decousus, Hervè, Prandoni, Paolo, Brenner, Benjamin, Barba, Raquel, Di Micco, Pierpaolo, Bertoletti, Laurent, Tzoran, Inna, Reis, Abilio, Bosevski, Marijan, Bounameaux, Henri, Malý, Radovan, Wells, Philip, Papadakis, Manolis, Aibar, M. A., Alfonso, M., Asensio-Cruz, M. I., Auguet, T., Arcelus, J. I., Barba, R., Barrón, M., Barrón-Andrés, B., Bascuñana, J., Blanco-Molina, A., Bueso, T., Cañas, I., Ceausu, A., Chic, N., Culla, A., del Pozo, R., del Toro, J., Díaz-Pedroche, M. C., Díaz-Peromingo, J. A., Duffort, M., Elias-Hernández, T., Falgá, C., Fernández-Aracil, C., Fernández-Capitán, C., Fidalgo, M. A., Font, C., Font, L., Gallego, P., García, M. A., García-Bragado, F., García-Rodenas, M., Gómez, V., González, J., Grau, E., Grimón, A., Guijarro, R., Guirado, L., Gutiérrez, J., Hernández-Comes, G., Hernández-Blasco, L., Hernando-López, E., Jara-Palomares, L., Jaras, M. J., Jiménez, D., Joya, M. D., Llamas, P., Lecumberri, R., Lobo, J. L., López-Jiménez, L., López-Reyes, R., López-Sáez, J. B., Lorente, M. A., Lorenzo, A., Maestre, A., Marchena, P. J., Martín, M., Martín-Martos, F., Monreal, M., Nieto, J. A., Nieto, S., Núñez, A., Núñez, M. J., Odriozola, M., Otalora, S., Otero, R., Ovejero, A., Pedrajas, J. M., Pérez, G., Pérez-Ductor, C., Peris, M. L., Porras, J. A., Reig, O., Riera-Mestre, A., Riesco, D., Rivas, A., Rodríguez-Dávila, M. A., Rosa, V., Ruiz-Artacho, P., Ruiz-Giménez, N., Sahuquillo, J. C., Sala-Sainz, M. C., Sampériz, A., Sánchez, R., Sanz, O., Soler, S., Sopeña, B., Suriñach, J. M., Tolosa, C., Trujillo-Santos, J., Uresandi, F., Valero, B., Valle, R., Vela, J., Vicente, P., Vidal, G., Villalobos, A., Villalta, J., Vanassche, T., Verhamme, P., Wells, P., Hirmerova, J., Malý, R., Salgado, E., Bertoletti, L., Bura-Riviere, A., Farge-Bancel, D., Hij, A., Mahé, I., Merah, A., Moustafa, F., Papadakis, M., Braester, A., Brenner, B., Tzoran, I., Antonucci, G., Barillari, G., Bertone, A., Bilora, F., Bortoluzzi, C., Ciammaichella, M., Di Girolamo, C., Di Micco, P., Duce, R., Ferrazzi, P., Giorgi-Pierfranceschi, M., Grandone, E., Lodigiani, C., Maida, R., Mastroiacovo, D., Pace, F., Pesavento, R., Pinelli, M., Poggio, R., Prandoni, P., Rota, L., Tiraferri, E., Tonello, D., Tufano, A., Visonà, A., Zalunardo, B., Drucka, E., Kigitovica, D., Skride, A., Sousa, M. S., Bosevski, M., Zdraveska, M., Bounameaux, H., and Mazzolai, L.

Published
2017
Full Text
View/download PDF

12. 108P Pathologic nodal positivity in patients with cT1-2 cN0 HER2+ breast cancer treated with upfront surgery or neoadjuvant anti-HER2-based therapy

Author

Martinez Saez, O., primary, Hernando Melia, C., additional, Rey, M., additional, Chic, N., additional, Martinez, M.T.M., additional, Cebrecos, I., additional, Bermejo De Las Heras, B., additional, Bargalló, X., additional, Burgués, O., additional, Ganau, S., additional, Úbeda, B., additional, Mollá, M., additional, Vidal-Siscart, S., additional, Sanfeliu Torres, E., additional, Gonzalez-Farre, B., additional, Vidal, M., additional, Adamo, B., additional, Munoz, M., additional, Prat, A., additional, and Cejalvo Andujar, J.M., additional

Published
2022
Full Text
View/download PDF

13. 147P Breast cancer in women with germline pathogenic variants: Frequency, clinical behavior, and outcomes of a consecutive series of patients from Spain

Author

Rodriguez Hernandez, A., primary, Braso Maristany, F., additional, Pastor, B., additional, Potrony, M., additional, Moreno, L., additional, Grau, E., additional, Puig-Butille, J.A., additional, Martinez Saez, O., additional, Conte, B., additional, Chic, N., additional, Vidal Losada, M.J., additional, Munoz, M., additional, Balaguer, F., additional, Prat, A., additional, and Adamo, B., additional

Published
2022
Full Text
View/download PDF

14. 132TiP HCB-ONC001 ELPIS TRIAL: Omission of surgery and sentinel lymph node dissection in clinically low-risk HER2-positive breast cancer with high HER2 addiction and a complete response following standard anti-HER2-based neoadjuvant therapy

Author

Pascual, T., primary, Chic, N., additional, Martinez Saez, O., additional, Sanfeliu Torres, E., additional, Adamo, B., additional, Cebrecos, I., additional, Mension, E., additional, Bargalló, X., additional, Caparros, X., additional, Ganau, S., additional, Gonzalez-Farre, B., additional, Mollá, M., additional, Oses, G., additional, Rodriguez, A.B., additional, Úbeda, B., additional, Vidal Losada, M.J., additional, Vidal-Siscart, S., additional, Munoz, M., additional, and Prat, A., additional

Published
2022
Full Text
View/download PDF

15. 10P Survival according to early ctDNA dynamics in advanced breast cancer (ABC) treated with endocrine therapy (ET) and a CDK4/6 inhibitor (CDK4/6i)

Author

Martinez Saez, O., primary, Felip Falgas, E., additional, Cappelletti, M., additional, Tolosa, P., additional, Brasó-Maristany, F., additional, Sanfeliu Torres, E., additional, Pascual, T., additional, Chic, N., additional, Vidal, M., additional, Adamo, B., additional, Munoz, M., additional, Faull, I., additional, Odegaard, J., additional, Patel, G., additional, McEwen, R., additional, Carroll, D., additional, Ciruelos, E.M., additional, Generali, D.G., additional, Margeli Vila, M., additional, and Prat, A., additional

Published
2022
Full Text
View/download PDF

17. Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation

Author

Decousus, Hervé, Prandoni, Paolo, Brenner, Benjamin, Barba, Raquel, Di Micco, Pierpaolo, Bertoletti, Laurent, Tzoran, Inna, Reis, Abilio, Bosevski, Marijan, Bounameaux, Henri, Malý, Radovan, Wells, Philip, Papadakis, Manolis, Adarraga, M.D., Aibar, M.A., Alfonso, M., Arcelus, J.I., Barba, R., Barrón, M., Barrón-Andrés, B., Bascuñana, J., Blanco-Molina, A., Bueso, T., Cañada, G., Cañas, I., Chic, N., del Pozo, R., del Toro, J., Díaz-Pedroche, M.C., Díaz-Peromingo, J.A., Falgá, C., Fernández-Capitán, C., Fidalgo, M.A., Font, C., Font, L., Gallego, P., García, A., García, M.A., García-Bragado, F., García-Brotons, P., Gavín, O., Gómez, C., Gómez, V., González, J., González-Marcano, D., Grau, E., Grimón, A., Guijarro, R., Gutiérrez, J., Hernández-Comes, G., Hernández-Blasco, L., Hermosa-Los Arcos, M.J., Jara-Palomares, L., Jaras, M.J., Jiménez, D., Joya, M.D., Llamas, P., Lecumberri, R., Lobo, J.L., López, P., López-Jiménez, L., López-Reyes, R., López-Sáez, J.B., Lorente, M.A., Lorenzo, A., Maestre, A., Marchena, P.J., Martín-Martos, F., Monreal, M., Nieto, J.A., Nieto, S., Núñez, A., Núñez, M.J., Odriozola, M., Otero, R., Pedrajas, J.M., Pérez, G., Pérez-Ductor, C., Peris, M.L., Porras, J.A., Reig, O., Riera-Mestre, A., Riesco, D., Rivas, A., Rodríguez, C., Rodríguez-Dávila, M.A., Rosa, V., Ruiz-Giménez, N., Sahuquillo, J.C., Sala-Sainz, M.C., Sampériz, A., Sánchez-Martínez, R., Sánchez Simón-Talero, R., Sanz, O., Soler, S., Suriñach, J.M., Torres, M.I., Trujillo-Santos, J., Uresandi, F., Valero, B., Valle, R., Vela, J., Vicente, M.P., Villalobos, A., Vanassche, T., Verhamme, P., Wells, P., Hirmerova, J., Malý, R., Tomko, T., del Pozo, G., Salgado, E., Sánchez, G.T., Bertoletti, L., Bura-Riviere, A., Mahé, I., Merah, A., Moustafa, F., Papadakis, M., Braester, A., Brenner, B., Tzoran, I., Antonucci, G., Barillari, G., Bilora, F., Bortoluzzi, C., Cattabiani, C., Ciammaichella, M., Di Biase, J., Di Micco, P., Duce, R., Ferrazzi, P., Giorgi-Pierfranceschi, M., Grandone, E., Imbalzano, E., Lodigiani, C., Maida, R., Mastroiacovo, D., Pace, F., Pesavento, R., Pinelli, M., Poggio, R., Prandoni, P., Rota, L., Tiraferri, E., Tonello, D., Tufano, A., Visonà, A., Zalunardo, B., Gibietis, V., Skride, A., Vitola, B., Monteiro, P., Ribeiro, J.L., Sousa, M.S., Bosevski, M., Zdraveska, M., Bounameaux, H., Calanca, L., Erdmann, A., Mazzolai, L., Fidalgo, Ángeles, Rivas, Agustina, Wells, Philip S., Gavín, Olga, Adarraga, María Dolores, Moustafa, Farès, and Monreal, Manuel

Published
2017
Full Text
View/download PDF

18. 120MO Prognostic value of immune gene-expression signatures (iGES) vs tumor-infiltrating lymphocytes (TILs) in early-stage HER2+ breast cancer: A combined analysis of CALGB 40601 (C40601) and PAMELA trials

Author

Fernandez-Martinez, A., primary, Pascual, T., additional, Singh, B., additional, Nuciforo, P., additional, Hoadley, K.A., additional, Rashid, N.U., additional, Spears, P.A., additional, Chic, N., additional, Krop, I., additional, Hillman, D., additional, Partridge, A., additional, Prat, A., additional, Carey, L.A., additional, and Perou, C.M., additional

Published
2021
Full Text
View/download PDF

19. Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy: ER activity in pre-menopausal HR+ breast cancer during CT

Author

Schettini, F., Chic, N., Bellet, M., Vidal, M., Oliveira, M., Perou, C.M., Saura, C., Sanfeliu, E., Gonz��lez-Farr��, B., Carey, L.A., Bras��-Maristany, F., Ciruelos, E., Mart��nez-S��ez, O., Pernas, S., Mu��oz, M., Soberino, J., Galv��n, P., Adamo, B., Mart��nez, D., Gavil��, J., Prat, A., Cort��s, J., and Pascual, T.

Subjects
skin and connective tissue diseases
Abstract

Background: Chemotherapy efficacy in early-stage hormone receptor-positive (HR+) breast cancer (BC) according to menopausal status needs a biological explanation. Methods: We compared early-stage HR+ BC biological features before and after (neo)adjuvant chemotherapy or endocrine therapy (ET), and assessed oestrogen receptor (ER) pathway activity in both pre- and post-menopausal patients. The nCounter platform was used to detect gene expression levels. Findings: In 106 post-menopausal patients with HR+/HER2-negative BC randomized to neoadjuvant chemotherapy or ET (letrozole+ribociclib), a total of 19 oestrogen-regulated genes, including progesterone receptor (PGR), were found downregulated in the ET-based arm-only. We confirmed this finding in an independent dataset of 20 letrozole-treated post-menopausal patients and found, conversely, an up-regulation of the same signature in HR+/HER2-negative MCF7 cell line treated with estradiol. PGR was found down-regulated by 2 weeks of ET+anti-HER2 therapy in pre-/post-menopausal patients with HR+/HER2-positive (HER2+) BC, while anti-HER2 therapy alone increased PGR expression in HR-negative/HER2+ BC. In 88 pre- and post-menopausal patients with newly diagnosed HR+/HER2-negative BC treated with chemotherapy, the 19 oestrogen-regulated genes were found significantly downregulated only in pre-menopausal patients. In progesterone receptor (PR)+/HER2-negative BC treated with neoadjuvant chemotherapy (n=40), tumours became PR-negative in 69.2% of pre-menopausal patients and 14.8% of post-menopausal patients (p=0.001). Finally, a mean decrease in PGR levels was only observed in pre-menopausal patients undergoing anti-HER2-based multi-agent chemotherapy. Interpretation: Chemotherapy reduces the expression of ER-regulated genes in pre-menopausal women suffering from hormone-dependent BC by supressing ovarian function. Further studies should test the value of chemotherapy in this patient population when ovarian function is suppressed by other methods. Funding: Instituto de Salud Carlos III, Breast Cancer Now, the Breast Cancer Research Foundation, the American Association for Cancer Research, Fundaci�� La Marat�� TV3, the European Union's Horizon 2020 Research and Innovation Programme, Pas a Pas, Save the Mama, Fundaci��n Cient��fica Asociaci��n Espa��ola Contra el C��ncer, PhD4MDgrant of ���Departament de Salut���, exp SLT008/18/00122, Fundaci��n SEOM and ESMO. Any views, opinions, findings, conclusions, or recommendations expressed in this material are those solely of the author(s)

Published
2021
Full Text
View/download PDF

21. Independent validation of the PAM50-based chemo-endocrine score (CES) in hormone receptor-positive HER2-positive breast cancer treated with neoadjuvant anti-HER2-based therapy

Author

Pascual T, Fernandez-Martinez A, Tanioka M, Dieci M, Pernas S, Gavila J, Guarnieri V, Cortes J, Villagrasa P, Chic N, Vidal M, Adamo B, Munoz M, Griguolo G, Llombart A, Conte P, Oliveira M, Conte B, Pare L, Galvan P, Carey L, Perou C, and Prat A

Subjects
behavior and behavior mechanisms, social sciences, skin and connective tissue diseases, behavioral disciplines and activities, humanities
Abstract

Purpose: We do not yet have validated biomarkers to predict response and outcome within hormone receptor-positive/HER2-positive (HR+/HER2+) breast cancer. The PAM50-based chemoendocrine score (CES) predicts chemo-endocrine sensitivity in hormone receptor-positive/HER2-negative (HR+/HER2+) breast cancer. Here, we evaluate the relationship of CES with response and survival in HR+/HER2+ breast cancer. Experimental Design: Intrinsic subtype and clinicopathologic data were obtained from seven studies in which patients were treated with HER2-targeted therapy either with endocrine therapy (ET) or with chemotherapy (CTX). CES was evaluated as a continuous variable and categorically from low to high scores [CES-C (chemo-sensitive), CES-U (uncertain), and CES-E (endocrine-sensitive)]. We first analyzed each dataset individually, and then all combined. Multivariable analyses were used to test CES association with pathologic complete response (pCR) and disease-free survival (DFS). Results: A total of 457 patients were included (112 with ET and 345 with CTX). In the combined cohort, CES-C, CES-U, and CES-E were identified in 60%, 23%, and 17% of the patients, respectively. High CES (i.e., CES-E) was associated with a lower probability of achieving pCR independently of clinical characteristics, therapy, intrinsic subtype, and study (adjusted OR = 0.42; P = 0.016). A total of 295 patients were analyzed for DFS with a median follow-up of 66 months. High CES was also associated with better DFS (adjusted HR, 0.174; P = 0.003) independently of pCR, clinical characteristics and intrinsic subtype. In patients with residual disease, the adjusted DFS HR of CES was 0.160 (P = 0.012). Conclusions: In HER2+/HR+ breast cancer, CES is useful for predicting chemo-endocrine sensitivity and provides additional prognostication beyond intrinsic subtype and clinicopathologic characteristics.

Published
2021
Full Text
View/download PDF

22. 275P Clinical and molecular impact of neoadjuvant chemotherapy (NACT) or endocrine therapy (NET) on hormone receptor positive (HR+)/HER2-negative (-) breast cancer (BC)

Author

Schettini, F., Brasó-Maristany, F., Pascual, T., Galván, P., Conte, B., Ghiglione, L., Falato, C., Martínez-Sáez, O., Chic, N., Rodriguez, A.B., Torres, E. Sanfeliu, Gonzalez-Farre, B., Losada, M.J. Vidal, Adamo, B., Cebrecos, I., Mension, E., Oses, G., Mollá, M., Munoz, M., and Prat, A.

Published
2023
Full Text
View/download PDF

23. Predictors of active cancer thromboembolic outcomes

Author

Tafur, A. J., Caprini, J. A., Cote, L., Trujillo-Santos, J., del Toro, J., Garcia-Bragado, F., Tolosa, C., Barillari, G., Visona, A., Monreal, M., Adarraga, M. D., Aibar, M. A., Alfonso, M., Arcelus, J. I., Ballaz, A., Barba, R., Barron, M., Barrn-Andres, B., Bascunana, J., Blanco-Molina, A., Canas, I., Chic, N., del Pozo, R., Diaz-Pedroche, M. C., Diaz-Peromingo, J. A., Falga, C., Fernandez-Aracil, C., Fernandez-Capitan, C., Fidalgo, M. A., Font, C., Font, L., Gallego, P., Garcia, I., Garcia, M. A., Garcia-Rodenas, M., Gavin, O., Gomez, C., Gomez, V., Gonzalez, J., Grau, E., Grimon, A., Guijarro, R., Guirado, L., Gutierrez, J., Hernandez-Comes, G., Hernandez-Blasco, L., Jara-Palomares, L., Jaras, M. J., Jimenez, D., Jimenez, J., Joya, M. D., Llamas, P., Lobo, J. L., Lopez, P., Lopez-Jimenez, L., Lopez-Reyes, R., Lopez-Saez, J. B., Lorente, M. A., Lorenzo, A., Lumbierres, M., Marchena, P. J., Martin-Martos, F., Mellado, M., Nieto, J. A., Nieto, S., Nunez, A., Nunez, M. J., Otalora, S., Otero, R., Ovejero, A., Pedrajas, J. M., Perez, G., Perez-Ductor, C., Peris, M. L., Pons, I., Porras, J. A., Reig, O., Riera-Mestre, A., Riesco, D., Rivas, A., Rodriguez, M., Rodriguez-Davila, M. A., Rosa, V., Ruiz-Artacho, P., Ruiz-Gimenez, N., Sahuquillo, J. C., Sala-Sainz, M. C., Samperiz, A., Sanchez-Martinez, R., Sanz, O., Soler, S., Sopena, B., Surinach, J. M., Torres, M. I., Uresandi, F., Usandizaga, E., Valero, B., Valle, R., Vela, J., Velez-Mendizabal, E., Vidal, G., Vila, M., Villalobos, A., Xifre, B., Vanassche, T., Verhamme, P., Yoo, H. H. B., Wells, P., Hirmerova, J., Maly, R., Salgado, E., Bertoletti, L., Bura-Riviere, A., Falvo, N., Farge-Bancel, D., Hij, A., Mahe, I., Moustafa, F., Braester, A., Brenner, B., Tzoran, I., Antonucci, G., Bilora, F., Bortoluzzi, C., Brandolin, B., Bucherini, E., Candeloro, G., Cattabiani, C., Ciammaichella, M., Dentali, F., Di Micco, P., Duce, R., Giorgi-Pierfranceschi, M., Grandone, E., Imbalzano, E., Lessiani, G., Maida, R., Mastroiacovo, D., Pace, F., Parisi, R., Pellegrinet, M., Pesavento, R., Pinelli, M., Poggio, R., Prandoni, P., Quintavalla, R., Rocci, A., Tiraferri, E., Tonello, D., Tufano, A., Gibietis, V., Skride, A., Vitola, B., Bosevski, M., Zdraveska, M., Bounameaux, H., Mazzolai, L., Tafur, A. J., Caprini, J. A., Cote, L., Trujillo-Santos, J., del Toro, J., Garcia-Bragado, F., Tolosa, C., Barillari, G., Visona, A., Monreal, M., Adarraga, M. D., Aibar, M. A., Alfonso, M., Arcelus, J. I., Ballaz, A., Barba, R., Barron, M., Barrn-Andres, B., Bascunana, J., Blanco-Molina, A., Canas, I., Chic, N., del Pozo, R., Diaz-Pedroche, M. C., Diaz-Peromingo, J. A., Falga, C., Fernandez-Aracil, C., Fernandez-Capitan, C., Fidalgo, M. A., Font, C., Font, L., Gallego, P., Garcia, I., Garcia, M. A., Garcia-Rodenas, M., Gavin, O., Gomez, C., Gomez, V., Gonzalez, J., Grau, E., Grimon, A., Guijarro, R., Guirado, L., Gutierrez, J., Hernandez-Comes, G., Hernandez-Blasco, L., Jara-Palomares, L., Jaras, M. J., Jimenez, D., Jimenez, J., Joya, M. D., Llamas, P., Lobo, J. L., Lopez, P., Lopez-Jimenez, L., Lopez-Reyes, R., Lopez-Saez, J. B., Lorente, M. A., Lorenzo, A., Lumbierres, M., Marchena, P. J., Martin-Martos, F., Mellado, M., Nieto, J. A., Nieto, S., Nunez, A., Nunez, M. J., Otalora, S., Otero, R., Ovejero, A., Pedrajas, J. M., Perez, G., Perez-Ductor, C., Peris, M. L., Pons, I., Porras, J. A., Reig, O., Riera-Mestre, A., Riesco, D., Rivas, A., Rodriguez, M., Rodriguez-Davila, M. A., Rosa, V., Ruiz-Artacho, P., Ruiz-Gimenez, N., Sahuquillo, J. C., Sala-Sainz, M. C., Samperiz, A., Sanchez-Martinez, R., Sanz, O., Soler, S., Sopena, B., Surinach, J. M., Torres, M. I., Uresandi, F., Usandizaga, E., Valero, B., Valle, R., Vela, J., Velez-Mendizabal, E., Vidal, G., Vila, M., Villalobos, A., Xifre, B., Vanassche, T., Verhamme, P., Yoo, H. H. B., Wells, P., Hirmerova, J., Maly, R., Salgado, E., Bertoletti, L., Bura-Riviere, A., Falvo, N., Farge-Bancel, D., Hij, A., Mahe, I., Moustafa, F., Braester, A., Brenner, B., Tzoran, I., Antonucci, G., Bilora, F., Bortoluzzi, C., Brandolin, B., Bucherini, E., Candeloro, G., Cattabiani, C., Ciammaichella, M., Dentali, F., Di Micco, P., Duce, R., Giorgi-Pierfranceschi, M., Grandone, E., Imbalzano, E., Lessiani, G., Maida, R., Mastroiacovo, D., Pace, F., Parisi, R., Pellegrinet, M., Pesavento, R., Pinelli, M., Poggio, R., Prandoni, P., Quintavalla, R., Rocci, A., Tiraferri, E., Tonello, D., Tufano, A., Gibietis, V., Skride, A., Vitola, B., Bosevski, M., Zdraveska, M., Bounameaux, H., and Mazzolai, L.

Subjects
Male, Risk, medicine.medical_specialty, 030204 cardiovascular system & hematology, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Predictive Value of Tests, Recurrence, Neoplasms, Thromboembolism, Internal medicine, Venous thrombosis, medicine, Humans, Cancer associated thrombosis, Recurrences, Registries, Mortality, Aged, Cancer, Aged, 80 and over, Prediction, Framingham Risk Score, business.industry, Mortality rate, Hematology, Middle Aged, Prognosis, medicine.disease, Survival Analysis, Predictive value, Thrombosis, United States, Surgery, Patient Outcome Assessment, Research Design, 030220 oncology & carcinogenesis, Cohort, Female, business, Biomarkers
Abstract

SummaryEven though the Khorana risk score (KRS) has been validated to predict against the development of VTE among patients with cancer, it has a low positive predictive value. It is also unknown whether the score predicts outcomes in patients with cancer with established VTE. We selected a cohort of patients with active cancer from the RIETE (Registro Informatizado Enfermedad TromboEmbolica) registry to assess the prognostic value of the KRS at inception in predicting the likelihood of VTE recurrences, major bleeding and mortality during the course of anticoagulant therapy. We analysed 7948 consecutive patients with cancer-associated VTE. Of these, 2253 (28 %) scored 0 points, 4550 (57 %) 1–2 points and 1145 (14 %) scored ≥3 points. During the course of anticoagulation, amongst patient with low, moderate and high risk KRS, the rate of VTE recurrences was of 6.21 (95 %CI: 4.99–7.63), 11.2 (95 %CI: 9.91–12.7) and 19.4 (95 %CI: 15.4–24.1) events per 100 patient-years; the rate of major bleeding of 5.24 (95 %CI: 4.13–6.56), 10.3 (95 %CI: 9.02–11.7) and 19.4 (95 %CI: 15.4–24.1) bleeds per 100 patient-years and the mortality rate of 25.3 (95 %CI: 22.8–28.0), 58.5 (95 %CI: 55.5–61.7) and 120 (95 %CI: 110–131) deaths per 100 patient-years, respectively. The C-statistic was 0.53 (0.50–0.56) for recurrent VTE, 0.56 (95 %CI: 0.54–0.59) for major bleeding and 0.54 (95 %CI: 0.52–0.56) for death. In conclusion, most VTEs occur in patients with low or moderate risk scores. The KRS did not accurately predict VTE recurrence, major bleeding, or mortality among patients with cancer-associated thrombosis.

Published
2017

24. 109P Subsequent therapies after progressing to CDK4/6 inhibition (CDK4/6i) in hormone receptor positive/HER2 negative (HR+/HER2-) advanced breast cancer (ABC)

Author

Laguna, J.C., primary, Brasó-Maristany, F., additional, Pascual, T., additional, Rodriguez Hernandez, A., additional, Chic, N., additional, Schettini, F., additional, Sanfeliu Torres, E., additional, Gonzalez-Farre, B., additional, Martínez, D., additional, Galván, P., additional, Díez-Guardia, V., additional, Adamo, B., additional, Vidal, M., additional, Guillen Sacoto, M.C., additional, Moreno, R., additional, Prat, A., additional, Muñoz, M., additional, and Martínez-Sáez, O., additional

Published
2021
Full Text
View/download PDF

25. 23P CDK4/6 inhibition and endocrine therapy (ET) in the HER2-enriched subtype (HER2-E) in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (ABC): A retrospective analysis of real-world data

Author

Martínez-Sáez, O., primary, Tolosa, P., additional, Sánchez De Torre, A., additional, Pascual, T., additional, Brasó-Maristany, F., additional, Rodriguez Hernandez, A., additional, Parrilla, L., additional, Roncero, A.M., additional, Ruano, Y., additional, Chic, N., additional, Schettini, F., additional, Laguna, J.C., additional, Sanfeliu Torres, E., additional, Gonzalez-Farre, B., additional, Vidal, M., additional, Adamo, B., additional, Guillen Sacoto, M.C., additional, Muñoz, M., additional, Prat, A., additional, and Ciruelos, E.M., additional

Published
2021
Full Text
View/download PDF

26. 177P COVID-19 pandemic impact in newly diagnosed breast cancer patients (BCP) at a third level hospital

Author

Guillen Sacoto, M.C., primary, Núñez-Manchón, E., additional, Bargalló, X., additional, Adamo, B., additional, Alonso, I., additional, Mollà, M., additional, Vidal, M., additional, Oses González, G., additional, Caparrós, X., additional, Gonzalez-Farre, B., additional, Chic, N., additional, Martínez-Sáez, O., additional, Ubeda, B., additional, Moreno, R., additional, Cebrecos, I., additional, Fontdevila Font, J., additional, Vidal-Sicart, S., additional, Rodríguez, A., additional, Prat, A., additional, and Muñoz, M., additional

Published
2021
Full Text
View/download PDF

27. 16P Understanding the biologic determinants of ribociclib efficacy in breast cancer

Author

Brasó-Maristany, F., primary, Palafox, M., additional, Monserrat, L., additional, Bellet, M., additional, Oliveira, M., additional, Capelán, M., additional, Galván, P., additional, Martínez, D., additional, Chic, N., additional, Viaplana, C., additional, Dienstmann, R., additional, Nuciforo, P., additional, Saura Manich, C., additional, Prat, A., additional, and Serra, V., additional

Published
2021
Full Text
View/download PDF

28. 40TiP SOLTI-1802 ONAWA trial: A window of opportunity trial of onapristone (ONA) in postmenopausal women with estrogen and progesterone receptor-positive/HER2-negative (ER+/PgR+/HER2-) early breast cancer (EBC)

Author

Bellet, M., primary, Morales Murillo, S., additional, Gasol Cudos, A., additional, Amillano, K., additional, Chic, N., additional, González-Farré, X., additional, Villagrasa, P., additional, Ferrero-Cafiero, J.M., additional, Pascual, T., additional, Prat, A., additional, Lange, C., additional, and Saura Manich, C., additional

Published
2021
Full Text
View/download PDF

31. 548P Molecular pre-screening using comprehensive gene panels offered by clinical trials (CT)

Author

Ruiz, I. Victoria, primary, Moreno, D., additional, Sole, P., additional, Gonzalez, B. Mellado, additional, Pineda, E., additional, Gaba, L., additional, Sauri, T., additional, Mileo, L. Ferrer, additional, Orrillo, M., additional, Maurel, J., additional, Oliveres, H., additional, Munoz-Mateu, M., additional, Losada, M.J. Vidal, additional, Saez, O. Martinez, additional, Chic, N., additional, Baste, N., additional, Segarra, N. Vinolas, additional, Reyes, R., additional, Prat, A., additional, and Garcia-Corbacho, J., additional

Published
2020
Full Text
View/download PDF

32. 23P Clinical, pathological and gene expression features of HER2-low breast cancer

Author

Schettini, F., primary, Chic, N., additional, Brasó-Maristany, F., additional, Paré, L., additional, Pascual, T., additional, Conte, B., additional, Martínez-Sáez, O., additional, Adamo, B., additional, Vidal, M., additional, Fernandez-Martinez, A., additional, González-Farré, B., additional, Sanfeliu, E., additional, Perrone, G., additional, Villagrasa, P., additional, Gavila Gregori, J., additional, Barrios, C.H., additional, Lluch, A., additional, Martin Jimenez, M., additional, De Placido, S., additional, and Prat, A., additional

Published
2020
Full Text
View/download PDF

33. 12P Gene expression profiling in early breast cancer treated with neoadjuvant ribociclib plus letrozole (R+L) versus chemotherapy (CT): A correlative analysis of the SOLTI-1402/CORALLEEN phase II trial

Author

Chic, N., primary, González-Farré, B., additional, Paré, L., additional, Pascual, T., additional, Saura, C., additional, Hernando Melia, C., additional, Muñoz, M., additional, Fernandez, P., additional, Martínez, D., additional, Sanfeliu, E., additional, Brasó-Maristany, F., additional, González-Farré, X., additional, Oliveira, M., additional, Gil-Gil, M., additional, Celiz, P., additional, Ciruelos, E.M., additional, Villagrasa, P., additional, Gavila Gregori, J., additional, and Prat, A., additional

Published
2020
Full Text
View/download PDF

34. 41P A window-of-opportunity study with atezolizumab and the oncolityc virus pelareorep in early breast cancer (REO-027, AWARE-1)

Author

Manso, L., primary, Villagrasa, P., additional, Chic, N., additional, Cejalvo, J.M., additional, Izarzugaza, Y., additional, Cantos, B., additional, Blanch, S., additional, Juan, M., additional, González-Farré, B., additional, Laeufle, R., additional, Nuovo, G., additional, Wilkinson, G., additional, Coffey, M., additional, González, A., additional, Martínez, D., additional, Paré, L., additional, Salvador, F., additional, González-Farré, X., additional, Prat, A., additional, and Gavila Gregori, J., additional

Published
2020
Full Text
View/download PDF

35. 19P PIK3CA mutations in HER2-positive early breast cancer patients enrolled in the adjuvant randomized short-HER study

Author

Guarneri, V., primary, Dieci, M.V., additional, Bisagni, G., additional, Brandes, A.A., additional, Frassoldati, A., additional, Cavanna, L., additional, Musolino, A., additional, Giotta, F., additional, Rimanti, A., additional, Garrone, O., additional, Bertone, E., additional, Cagossi, K., additional, Nanni, O., additional, Piacentini, F., additional, Orvieto, E., additional, Curtarello, M., additional, Chic, N., additional, D'Amico, R., additional, Prat, A., additional, and Conte, P.F., additional

Published
2020
Full Text
View/download PDF

36. 8P Characterization of immune microenvironment before and following anti-HER2 neoadjuvant therapy (NAT)

Author

Griguolo, G., primary, Serna, G., additional, Pascual, T., additional, Fasani, R., additional, Chic, N., additional, Paré, L., additional, Pernas, S., additional, Muñoz, M., additional, Oliveira, M., additional, Vidal, M., additional, Llombart Cussac, A., additional, Cortés, J., additional, Galván, P., additional, Bermejo, B., additional, Martínez, N., additional, López, R., additional, Morales, S., additional, Villagrasa, P., additional, Prat, A., additional, and Nuciforo, P., additional

Published
2020
Full Text
View/download PDF

37. 15P The CelTIL score as an early predictor of anti-tumour response following neoadjuvant therapy (NAT): A SOLTI biomarker analysis

Author

González-Farré, B., primary, Nuciforo, P., additional, Pare Brunet, L., additional, Cortés, J., additional, Llombart Cussac, A., additional, Gavila Gregori, J., additional, Sanfeliu, E., additional, Chic, N., additional, Vidal, M., additional, Adamo, B., additional, Muñoz, M., additional, Galván, P., additional, Martínez, D., additional, Villagrasa, P., additional, Pascual, T., additional, and Prat, A., additional

Published
2020
Full Text
View/download PDF

38. 5P Circulating tumour DNA (ctDNA) dynamics using a standardized multi-gene panel in advanced breast cancer patients (pts) treated with CDK4/6 inhibitors (CDK4/6i)

Author

Martínez-Sáez, O., primary, Pascual, T., additional, Brasó-Maristany, F., additional, Chic, N., additional, González-Farré, B., additional, Sanfeliu, E., additional, Rodríguez, A., additional, Martínez, D., additional, Galván, P., additional, Rodriguez Hernandez, A., additional, Schettini, F., additional, Conte, B., additional, Vidal, M.J., additional, Adamo, B., additional, Muñoz, M., additional, Moreno, R., additional, Ciruelos, E.M., additional, Faull, I., additional, Odegaard, J., additional, and Prat, A., additional

Published
2020
Full Text
View/download PDF

39. 168P Development of a combined clinical model to predict progression-free survival (PFS) in advanced breast cancer (ABC) treated with CDK4/6 inhibitors (CDK4/6i)

Author

Martínez-Sáez, O., primary, Menichetti, A., additional, Pare Brunet, L., additional, Griguolo, G., additional, Rodriguez Hernandez, A., additional, Pascual, T., additional, Dieci, M.V., additional, Conte, P.F., additional, Giorgi, C.A., additional, Brasó-Maristany, F., additional, Chic, N., additional, Martínez, D., additional, Rodríguez, A., additional, Schettini, F., additional, Conte, B., additional, Vidal, M., additional, Adamo, B., additional, Muñoz, M., additional, Prat, A., additional, and Guarneri, V., additional

Published
2020
Full Text
View/download PDF

40. Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism

Author

Medicina i Cirurgia, Universitat Rovira i Virgili, Barrios D., Chavant J., Jiménez D., Bertoletti L., Rosa-Salazar V., Muriel A., Viallon A., Fernández-Capitán C., Yusen R.D., Monreal M., Decousus H., Prandoni P., Brenner B., Barba R., Di Micco P., Tzoran I., Reis A., Bosevski M., Bounameaux H., Malý R., Wells P., Verhamme P., Adarraga M.D., Aibar M.A., Alfonso M., Arcelus J.I., Azcarate-Agüero P.M., Ballaz A., Barrón M., Barrón-Andrés B., Bascuñana J., Blanco-Molina A., Cañada G., Cañas I., Casado I., Chic N., del Pozo R., del Toro J., Díaz-Pedroche M.C., Díaz-Peromingo J.A., Barrios D., Chavant J., Jiménez D., Bertoletti L., Rosa-Salazar V., Muriel A., Viallon A., Fernández-Capitán C., Yusen R.D., Monreal M., Decousus H., Prandoni P., Brenner B., Barba R., Di Micco P., Tzoran I., Reis A., Bosevski M., Bounameaux H., Malý R., Wells P., Verhamme P., Adarraga M.D., Aibar M.A., Alfonso M., Arcelus J.I., Azcarate-Agüero P.M., Ballaz A., Barrón M., Barrón-Andrés B., Bascuñana J., Blanco-Molina A., Cañada G., Cañas I., Casado I., Chic N., del Pozo R., del Toro J., Díaz-Pedroche M.C., Díaz-Peromingo J.A., Barrios D., Chavant J., Jiménez D., Bertoletti L., Rosa-Salazar V., Muriel A., Viallon A., Fernández-Capitán C., Yusen R.D., Monreal M., Decousus H., Prandoni P., Brenner B., Barba R., Di Micco P., Tzoran I., Reis A., Bosevski M., Bounameaux H., Malý R., Medicina i Cirurgia, Universitat Rovira i Virgili, and Barrios D., Chavant J., Jiménez D., Bertoletti L., Rosa-Salazar V., Muriel A., Viallon A., Fernández-Capitán C., Yusen R.D., Monreal M., Decousus H., Prandoni P., Brenner B., Barba R., Di Micco P., Tzoran I., Reis A., Bosevski M., Bounameaux H., Malý R., Wells P., Verhamme P., Adarraga M.D., Aibar M.A., Alfonso M., Arcelus J.I., Azcarate-Agüero P.M., Ballaz A., Barrón M., Barrón-Andrés B., Bascuñana J., Blanco-Molina A., Cañada G., Cañas I., Casado I., Chic N., del Pozo R., del Toro J., Díaz-Pedroche M.C., Díaz-Peromingo J.A., Barrios D., Chavant J., Jiménez D., Bertoletti L., Rosa-Salazar V., Muriel A., Viallon A., Fernández-Capitán C., Yusen R.D., Monreal M., Decousus H., Prandoni P., Brenner B., Barba R., Di Micco P., Tzoran I., Reis A., Bosevski M., Bounameaux H., Malý R., Wells P., Verhamme P., Adarraga M.D., Aibar M.A., Alfonso M., Arcelus J.I., Azcarate-Agüero P.M., Ballaz A., Barrón M., Barrón-Andrés B., Bascuñana J., Blanco-Molina A., Cañada G., Cañas I., Casado I., Chic N., del Pozo R., del Toro J., Díaz-Pedroche M.C., Díaz-Peromingo J.A., Barrios D., Chavant J., Jiménez D., Bertoletti L., Rosa-Salazar V., Muriel A., Viallon A., Fernández-Capitán C., Yusen R.D., Monreal M., Decousus H., Prandoni P., Brenner B., Barba R., Di Micco P., Tzoran I., Reis A., Bosevski M., Bounameaux H., Malý R.

Abstract

Background Evidence-based recommendations do not adequately address the treatment of right heart thrombi in patients who present with acute symptomatic pulmonary embolism. Methods This study included patients who had acute pulmonary embolism associated with right heart thrombi and participated in the Registro Informatizado de la Enfermedad TromboEmbólica registry. We assessed the effectiveness of anticoagulation versus reperfusion treatment for the outcomes of all-cause mortality, pulmonary embolism-related mortality, recurrent venous thromboembolism, and major bleeding rates through 30 days after initiation of pulmonary embolism treatment. We used propensity score matching to adjust for the likelihood of receiving reperfusion treatment. Results Of 325 patients with pulmonary embolism and right heart thrombi, 255 (78%; 95% confidence interval, 74-83) received anticoagulation and 70 (22%; 95% confidence interval, 17-26) also received reperfusion treatment. Propensity score-matched pairs analyses did not detect a statistically lower risk of all-cause death (6.2% vs 14%, P = .15) or pulmonary embolism-related mortality (4.7% vs 7.8%; P = .47) for reperfusion compared with anticoagulation. Of the patients who received reperfusion treatment, 6.2% had a recurrence during the study follow-up period, compared with 0% of those who received anticoagulation (P = .049). The incidence of major bleeding events was not statistically different between the 2 treatment groups (3.1% vs 3.1%; P = 1.00). Conclusions In patients with pulmonary embolism and right heart thrombi, no significant difference was found between reperfusion therapy and anticoagulant therapy for mortality and bleeding. The risk of recurrences was significantly higher for reperfusion therapy compared with anticoagulati

Published
2017

41. Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation

Author

Medicina i Cirurgia, Universitat Rovira i Virgili, Tzoran I., Papadakis M., Brenner B., Fidalgo Á., Rivas A., Wells P.S., Gavín O., Adarraga M.D., Moustafa F., Monreal M., Decousus H., Prandoni P., Barba R., Di Micco P., Bertoletti L., Reis A., Bosevski M., Bounameaux H., Malý R., Wells P., Aibar M.A., Alfonso M., Arcelus J.I., Barrón M., Barrón-Andrés B., Bascuñana J., Blanco-Molina A., Bueso T., Cañada G., Cañas I., Chic N., del Pozo R., del Toro J., Díaz-Pedroche M.C., Díaz-Peromingo J.A., Falgá C., Fernández-Capitán C., Fidalgo M.A., Font C., Font L., Tzoran I., Papadakis M., Brenner B., Fidalgo Á., Rivas A., Wells P.S., Gavín O., Adarraga M.D., Moustafa F., Monreal M., Decousus H., Prandoni P., Barba R., Di Micco P., Bertoletti L., Reis A., Bosevski M., Bounameaux H., Malý R., Wells P., Aibar M.A., Alfonso M., Arcelus J.I., Barrón M., Barrón-Andrés B., Bascuñana J., Blanco-Molina A., Bueso T., Cañada G., Cañas I., Chic N., del Pozo R., del Toro J., Díaz-Pedroche M.C., Díaz-Peromingo J.A., Falgá C., Fernández-Capitán C., Fidalgo M.A., Font C., Font L., Tzoran I., Papadakis M., Brenner B., Fidalgo Á., Rivas A., Wells P.S., Gavín O., Adarraga M.D., Moustafa F., Monreal M., Decousus H., Prandoni P., Barba R., Di Micco P., Bertoletti L., Reis A., Bosevski M., Bounameaux H., Malý R., Wells P., Medicina i Cirurgia, Universitat Rovira i Virgili, and Tzoran I., Papadakis M., Brenner B., Fidalgo Á., Rivas A., Wells P.S., Gavín O., Adarraga M.D., Moustafa F., Monreal M., Decousus H., Prandoni P., Barba R., Di Micco P., Bertoletti L., Reis A., Bosevski M., Bounameaux H., Malý R., Wells P., Aibar M.A., Alfonso M., Arcelus J.I., Barrón M., Barrón-Andrés B., Bascuñana J., Blanco-Molina A., Bueso T., Cañada G., Cañas I., Chic N., del Pozo R., del Toro J., Díaz-Pedroche M.C., Díaz-Peromingo J.A., Falgá C., Fernández-Capitán C., Fidalgo M.A., Font C., Font L., Tzoran I., Papadakis M., Brenner B., Fidalgo Á., Rivas A., Wells P.S., Gavín O., Adarraga M.D., Moustafa F., Monreal M., Decousus H., Prandoni P., Barba R., Di Micco P., Bertoletti L., Reis A., Bosevski M., Bounameaux H., Malý R., Wells P., Aibar M.A., Alfonso M., Arcelus J.I., Barrón M., Barrón-Andrés B., Bascuñana J., Blanco-Molina A., Bueso T., Cañada G., Cañas I., Chic N., del Pozo R., del Toro J., Díaz-Pedroche M.C., Díaz-Peromingo J.A., Falgá C., Fernández-Capitán C., Fidalgo M.A., Font C., Font L., Tzoran I., Papadakis M., Brenner B., Fidalgo Á., Rivas A., Wells P.S., Gavín O., Adarraga M.D., Moustafa F., Monreal M., Decousus H., Prandoni P., Barba R., Di Micco P., Bertoletti L., Reis A., Bosevski M., Bounameaux H., Malý R., Wells P.

Abstract

Background Individuals with factor V Leiden or prothrombin G20210A mutations are at a higher risk to develop venous thromboembolism. However, the influence of these polymorphisms on patient outcome during anticoagulant therapy has not been consistently explored. Methods We used the Registro Informatizado de Enfermedad TromboEmbólica database to compare rates of venous thromboembolism recurrence and bleeding events occurring during the anticoagulation course in factor V Leiden carriers, prothrombin mutation carriers, and noncarriers. Results Between March 2001 and December 2015, 10,139 patients underwent thrombophilia testing. Of these, 1384 were factor V Leiden carriers, 1115 were prothrombin mutation carriers, and 7640 were noncarriers. During the anticoagulation course, 160 patients developed recurrent deep vein thrombosis and 94 patients developed pulmonary embolism (16 died); 154 patients had major bleeding (10 died), and 291 patients had nonmajor bleeding. On multivariable analysis, factor V Leiden carriers had a similar rate of venous thromboembolism recurrence (adjusted hazard ratio [HR], 1.16; 95% confidence interval [CI], 0.82-1.64), half the rate of major bleeding (adjusted HR, 0.50; 95% CI, 0.25-0.99) and a nonsignificantly lower rate of nonmajor bleeding (adjusted HR, 0.66; 95% CI, 0.43-1.01) than noncarriers. Prothrombin mutation carriers and noncarriers had a comparable rate of venous thromboembolism recurrence (adjusted HR, 1.00; 95% CI, 0.68-1.48), major bleeding (adjusted HR, 0.75; 95% CI, 0.42-1.34), and nonmajor bleeding events (adjusted HR, 1.10; 95% CI, 0.77-1.57). Conclusions During the anticoagulation course, factor V Leiden carriers had a similar risk for venous thromboembolism recurrence and half the risk for major bleeding compared with noncarr

Published
2017

42. Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism

Author

Universitat Rovira i Virgili, Barrios D., Chavant J., Jiménez D., Bertoletti L., Rosa-Salazar V., Muriel A., Viallon A., Fernández-Capitán C., Yusen R.D., Monreal M., Decousus H., Prandoni P., Brenner B., Barba R., Di Micco P., Tzoran I., Reis A., Bosevski M., Bounameaux H., Malý R., Wells P., Verhamme P., Adarraga M.D., Aibar M.A., Alfonso M., Arcelus J.I., Azcarate-Agüero P.M., Ballaz A., Barrón M., Barrón-Andrés B., Bascuñana J., Blanco-Molina A., Cañada G., Cañas I., Casado I., Chic N., del Pozo R., del Toro J., Díaz-Pedroche M.C., Díaz-Peromingo J.A., Barrios D., Chavant J., Jiménez D., Bertoletti L., Rosa-Salazar V., Muriel A., Viallon A., Fernández-Capitán C., Yusen R.D., Monreal M., Decousus H., Prandoni P., Brenner B., Barba R., Di Micco P., Tzoran I., Reis A., Bosevski M., Bounameaux H., Malý R., Wells P., Verhamme P., Adarraga M.D., Aibar M.A., Alfonso M., Arcelus J.I., Azcarate-Agüero P.M., Ballaz A., Barrón M., Barrón-Andrés B., Bascuñana J., Blanco-Molina A., Cañada G., Cañas I., Casado I., Chic N., del Pozo R., del Toro J., Díaz-Pedroche M.C., Díaz-Peromingo J.A., Barrios D., Chavant J., Jiménez D., Bertoletti L., Rosa-Salazar V., Muriel A., Viallon A., Fernández-Capitán C., Yusen R.D., Monreal M., Decousus H., Prandoni P., Brenner B., Barba R., Di Micco P., Tzoran I., Reis A., Bosevski M., Bounameaux H., Malý R., Universitat Rovira i Virgili, and Barrios D., Chavant J., Jiménez D., Bertoletti L., Rosa-Salazar V., Muriel A., Viallon A., Fernández-Capitán C., Yusen R.D., Monreal M., Decousus H., Prandoni P., Brenner B., Barba R., Di Micco P., Tzoran I., Reis A., Bosevski M., Bounameaux H., Malý R., Wells P., Verhamme P., Adarraga M.D., Aibar M.A., Alfonso M., Arcelus J.I., Azcarate-Agüero P.M., Ballaz A., Barrón M., Barrón-Andrés B., Bascuñana J., Blanco-Molina A., Cañada G., Cañas I., Casado I., Chic N., del Pozo R., del Toro J., Díaz-Pedroche M.C., Díaz-Peromingo J.A., Barrios D., Chavant J., Jiménez D., Bertoletti L., Rosa-Salazar V., Muriel A., Viallon A., Fernández-Capitán C., Yusen R.D., Monreal M., Decousus H., Prandoni P., Brenner B., Barba R., Di Micco P., Tzoran I., Reis A., Bosevski M., Bounameaux H., Malý R., Wells P., Verhamme P., Adarraga M.D., Aibar M.A., Alfonso M., Arcelus J.I., Azcarate-Agüero P.M., Ballaz A., Barrón M., Barrón-Andrés B., Bascuñana J., Blanco-Molina A., Cañada G., Cañas I., Casado I., Chic N., del Pozo R., del Toro J., Díaz-Pedroche M.C., Díaz-Peromingo J.A., Barrios D., Chavant J., Jiménez D., Bertoletti L., Rosa-Salazar V., Muriel A., Viallon A., Fernández-Capitán C., Yusen R.D., Monreal M., Decousus H., Prandoni P., Brenner B., Barba R., Di Micco P., Tzoran I., Reis A., Bosevski M., Bounameaux H., Malý R.

Abstract

Background Evidence-based recommendations do not adequately address the treatment of right heart thrombi in patients who present with acute symptomatic pulmonary embolism. Methods This study included patients who had acute pulmonary embolism associated with right heart thrombi and participated in the Registro Informatizado de la Enfermedad TromboEmbólica registry. We assessed the effectiveness of anticoagulation versus reperfusion treatment for the outcomes of all-cause mortality, pulmonary embolism-related mortality, recurrent venous thromboembolism, and major bleeding rates through 30 days after initiation of pulmonary embolism treatment. We used propensity score matching to adjust for the likelihood of receiving reperfusion treatment. Results Of 325 patients with pulmonary embolism and right heart thrombi, 255 (78%; 95% confidence interval, 74-83) received anticoagulation and 70 (22%; 95% confidence interval, 17-26) also received reperfusion treatment. Propensity score-matched pairs analyses did not detect a statistically lower risk of all-cause death (6.2% vs 14%, P = .15) or pulmonary embolism-related mortality (4.7% vs 7.8%; P = .47) for reperfusion compared with anticoagulation. Of the patients who received reperfusion treatment, 6.2% had a recurrence during the study follow-up period, compared with 0% of those who received anticoagulation (P = .049). The incidence of major bleeding events was not statistically different between the 2 treatment groups (3.1% vs 3.1%; P = 1.00). Conclusions In patients with pulmonary embolism and right heart thrombi, no significant difference was found between reperfusion therapy and anticoagulant therapy for mortality and bleeding. The risk of recurrences was significantly higher for reperfusion therapy compared with anticoagulati

Published
2017

43. Development of a Risk Prediction Score for Occult Cancer in Patients With VTE

Author

Universitat Rovira i Virgili, Jara-Palomares L., Otero R., Jimenez D., Carrier M., Tzoran I., Brenner B., Margeli M., Praena-Fernandez J.M., Grandone E., Monreal M., Decousus H., Prandoni P., Barba R., Di Micco P., Bertoletti L., Reis A., Bosevski M., Bounameaux H., Malý R., Wells P., Papadakis M., Aibar M.A., Alfonso M., Asensio-Cruz M.I., Auguet T., Arcelus J.I., Barrón M., Barrón-Andrés B., Bascuñana J., Blanco-Molina A., Bueso T., Cañas I., Ceausu A., Chic N., Culla A., del Pozo R., del Toro J., Díaz-Pedroche M.C., Díaz-Peromingo J.A., Duffort M., Jara-Palomares L., Otero R., Jimenez D., Carrier M., Tzoran I., Brenner B., Margeli M., Praena-Fernandez J.M., Grandone E., Monreal M., Decousus H., Prandoni P., Barba R., Di Micco P., Bertoletti L., Reis A., Bosevski M., Bounameaux H., Malý R., Wells P., Papadakis M., Aibar M.A., Alfonso M., Asensio-Cruz M.I., Auguet T., Arcelus J.I., Barrón M., Barrón-Andrés B., Bascuñana J., Blanco-Molina A., Bueso T., Cañas I., Ceausu A., Chic N., Culla A., del Pozo R., del Toro J., Díaz-Pedroche M.C., Díaz-Peromingo J.A., Duffort M., Jara-Palomares L., Otero R., Jimenez D., Carrier M., Tzoran I., Brenner B., Margeli M., Praena-Fernandez J.M., Grandone E., Monreal M., Decousus H., Prandoni P., Barba R., Di Micco P., Bertoletti L., Reis A., Bosevski M., Bounameaux H., Malý R., Universitat Rovira i Virgili, and Jara-Palomares L., Otero R., Jimenez D., Carrier M., Tzoran I., Brenner B., Margeli M., Praena-Fernandez J.M., Grandone E., Monreal M., Decousus H., Prandoni P., Barba R., Di Micco P., Bertoletti L., Reis A., Bosevski M., Bounameaux H., Malý R., Wells P., Papadakis M., Aibar M.A., Alfonso M., Asensio-Cruz M.I., Auguet T., Arcelus J.I., Barrón M., Barrón-Andrés B., Bascuñana J., Blanco-Molina A., Bueso T., Cañas I., Ceausu A., Chic N., Culla A., del Pozo R., del Toro J., Díaz-Pedroche M.C., Díaz-Peromingo J.A., Duffort M., Jara-Palomares L., Otero R., Jimenez D., Carrier M., Tzoran I., Brenner B., Margeli M., Praena-Fernandez J.M., Grandone E., Monreal M., Decousus H., Prandoni P., Barba R., Di Micco P., Bertoletti L., Reis A., Bosevski M., Bounameaux H., Malý R., Wells P., Papadakis M., Aibar M.A., Alfonso M., Asensio-Cruz M.I., Auguet T., Arcelus J.I., Barrón M., Barrón-Andrés B., Bascuñana J., Blanco-Molina A., Bueso T., Cañas I., Ceausu A., Chic N., Culla A., del Pozo R., del Toro J., Díaz-Pedroche M.C., Díaz-Peromingo J.A., Duffort M., Jara-Palomares L., Otero R., Jimenez D., Carrier M., Tzoran I., Brenner B., Margeli M., Praena-Fernandez J.M., Grandone E., Monreal M., Decousus H., Prandoni P., Barba R., Di Micco P., Bertoletti L., Reis A., Bosevski M., Bounameaux H., Malý R.

Abstract

The benefits of a diagnostic workup for occult cancer in patients with VTE are controversial. Our aim was to provide and validate a risk score for occult cancer in patients with VTE.We designed a nested case-control study in a cohort of patients with VTE included in the RIETE (Registro Informatizado Enfermedad TromboEmbólica) registry from 2001 to 2014. Cases included cancer detected beyond the first 30 days and up to 24 months after VTE. Control subjects were defined as patients with VTE with no cancer in the same period.Of 5,863 eligible patients, 444 (7.6%; 95% CI, 6.8%-8.2%) were diagnosed with occult cancer. On multivariable analysis, variables selected were male sex, age > 70 years, chronic lung disease, anemia, elevated platelet count, prior VTE, and recent surgery. We built a risk score assigning points to each variable. Internal validity was confirmed using bootstrap analysis. The proportion of patients with cancer who scored ? 2 points was 5.8% (241 of 4,150) and that proportion in those who scored ? 3 points was 12% (203 of 1,713). We also identified scores divided by sex and age subgroups.This is the first risk score that has identified patients with VTE who are at increased risk for occult cancer. Our score needs to be externally validated.Copyright © 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Published
2017

44. Easy Java/JavaScript Simulations as a tool for Learning Analytics

Author

Esquembre, Francisco, Clemente, F��lix J. Garc��a, Chic��n, Rafael, Wee, Lawrence, Kwang, Leong Tze, and Tan, Darren

Subjects
FOS: Computer and information sciences, Computer Science - Computers and Society, Physics Education (physics.ed-ph), Computers and Society (cs.CY), Physics - Physics Education, FOS: Physical sciences
Abstract

In this paper we introduce the new and planned features of Easy Java/JavaScript Simulations (EJS) to support Learning Analytics (LA) and Educational Data Mining (EDM) research and practice in the use of simulations for the teaching and self-learning of natural sciences and engineering. Simulations created with EJS can now be easily embedded in a popular Learning Management System using a new plug-in that allows creation of full-fledged instructional units that also collect and record fine-grained, instructional-savvy data of the students interaction with the simulation. The resulting data can then be mined to obtain information about students performance, behaviors, or learning procedures with the intention to support student learning, provide instructors with timely information about student performance, and also help optimize the pedagogic design of the simulations themselves. We describe the current development and architecture, as well as future directions for testing and extending the current capabilities of EJS as a modelling and authoring tool to support LA and EDM research and practice in the use of simulations for teaching science, in particular in the context of the increasingly popular online learning platforms., 7 pages, 4 figures, conference paper Shih, J. L. et al. (Eds.) (2019). Proceedings of the 27th International Conference on Computers in Education. Taiwan: Asia-Pacific Society for Computers in Education

Published
2019

45. ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): A retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials

Author

Chic, N., primary, Pascual, T., additional, Brasó-Maristany, F., additional, Villagrasa Gonzalez, P., additional, Pare Brunet, L., additional, Schettini, F., additional, Conte, B., additional, Adamo, B., additional, Vidal, M., additional, Muñoz, M., additional, Martínez, O., additional, Gonzalez-Farre, B., additional, Cortés, J., additional, Llombart-Cussac, A., additional, Rodrik-Outmezguine, V., additional, Izquierdo Delso, M.A., additional, Schiff, R., additional, Osborne, C.K., additional, Rimawi, M., additional, and Prat, A., additional

Published
2019
Full Text
View/download PDF

46. PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: A meta-analysis

Author

Schettini, F., primary, Pascual, T., additional, Chic, N., additional, Conte, B., additional, Martínez, O., additional, Adamo, B., additional, Vidal, M., additional, Muñoz, M., additional, Fernández-Martínez, A., additional, Griguolo, G., additional, Guarneri, V., additional, Conte, P.F., additional, De Placido, S., additional, Carey, L., additional, Perou, C.M., additional, and Prat, A., additional

Published
2019
Full Text
View/download PDF

50. Abstract P2-08-17: Tumor inflammation signature (TIS), intrinsic subtypes and chemo-endocrine score (CES) in metastatic triple-negative breast cancer (mTNBC): A SOLTI biomarker program study

Author

Pascual, T, primary, Pernaut, C, additional, Tolosa, P, additional, Galvan, P, additional, Bárcena, C, additional, Vidal, M, additional, Manso, L, additional, Adamo, B, additional, Dueñas, M, additional, Muñoz, M, additional, Chic, N, additional, Gonzalez-Farre, B, additional, Villagrasa, P, additional, Ciruelos, E, additional, and Prat, A, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results